Scientists at the University of Cambridge have created what they describe as a fundamentally new vaccine design using artificial intelligence, representing the first instance in which an antigen—the critical immune-training component of a vaccine—was designed entirely by AI and subsequently trialled in people.
The vaccine was engineered to protect against a broad range of coronaviruses, encompassing all Covid variants as well as animal viruses with pandemic potential. The approach differs from traditional vaccine development, which typically focuses on current virus strains. Instead, the Cambridge team analyzed genetic codes from multiple coronaviruses identified through surveillance programs and used artificial intelligence to design a “super-antigen” capable of training the immune system against an entire virus family, even accounting for mutations or cross-species transmission.
Initial human trials involved 39 participants and assessed vaccine safety, with results published in the Journal of Infection. A second trial involving approximately 200 people will provide additional data on immune system response. While researchers noted the immune impact was “modest,” the findings have generated significant interest among the scientific community. Prof Saul Faust, who conducted some trials at the University of Southampton, described the AI design approach as having “definite potential” and noted the technology performs particularly well for pandemic-preparedness vaccines amid viral mutation.
The research team is expanding efforts to develop additional vaccines using this technology, including universal seasonal flu vaccines requiring no annual adaptation and protections against H5N1 bird flu and viral haemorrhagic fevers including Ebola. External experts have praised the approach as potentially transformative for vaccine development, with Prof Andy Pollard from Oxford noting that AI could accelerate development timelines and enhance predictions of immune response, ultimately saving lives. Government officials have characterized the work as advancing British scientific capabilities in vaccine innovation.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI